2,261
Views
23
CrossRef citations to date
0
Altmetric
Review Article

Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer

, &
Pages 351-362 | Received 13 Nov 2015, Accepted 05 Jan 2016, Published online: 24 Feb 2016

References

  • Babjuk M, Böhle A, Burger M, Compérat E, Kaasinen E, Palou J, et al. Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS). Eur Urol 2015. http://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-muscle-invasive-Bladder-Cancer-2015-v1.pdf
  • Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–75; discussion 475–7
  • Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Ojea A, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette–Guerin: External validation of the EORTC risk tables. Eur Urol 2011;60:423–30
  • Slater SE, Patel P, Viney R, Foster M, Porfiri E, James ND, et al. The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. Ann R Coll Surg Engl 2014;96:415–19
  • England HR, Anderson JD, Minasian H, Marshall VR, Molland EA, Blandy JP. The therapeutic application of hyperthermia in the bladder. Br J Urol 1975;47:849–52
  • Soria F, Milla P, Fiorito C, Pisano F, Sogni F, Di Marco M, et al. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: A phase I–II study. World J Urol 2015. doi: 10.1007/s00345-015-1595-3. Epub 2015 May 31
  • Sousa A, Inman BA, Pineiro I, Monserrat V, Perez A, Aparici V, et al. A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. Int J Hyperthermia 2014;30:166–70
  • Oliveira TR, Stauffer PR, Lee CT, Landon CD, Etienne W, Ashcraft KA, et al. Magnetic fluid hyperthermia for bladder cancer: A preclinical dosimetry study. Int J Hyperthermia 2013;29:835–44
  • Inman BA, Stauffer PR, Craciunescu OA, Maccarini PF, Dewhirst MW, Vujaskovic Z. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia 2014;30:171–5
  • Colombo R, Lev A, Da Pozzo LF, Freschi M, Gallus G, Rigatti P. A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol 1995;153:959–63
  • Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: A systematic review. Eur Urol 2011;60:81–93
  • Mazzoleni F, Albo G, Verweij F, Botteri E, Detti S, Colombo R, et al. Thermo-chemotherapy for superficial transitional cell carcinoma of the bladder. Results of a multicentric clinical study: ‘Synergo lombardia’. Anticancer Res 2010;30:1538–9
  • Paroni R, Salonia A, Lev A, Da Pozzo LF, Cighetti G, Montorsi F, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001;52:273–8
  • Haveman J, Smals OA, Rodermond HM. Effects of hyperthermia on the rat bladder: A pre-clinical study on thermometry and functional damage after treatment. Int J Hyperthermia 2003;19:45–57
  • Matzkin H, Rangel MC, Soloway MS. In vitro study of the effect of hyperthermia on normal bladder cell line and on five different transitional cell carcinoma cell lines. J Urol 1992;147:1671–4
  • van der Heijden AG, Hulsbergen-Van de Kaa CA, Witjes JA. The influence of thermo-chemotherapy on bladder tumours: An immunohistochemical analysis. World J Urol 2007;25:303–8
  • van der Heijden AG, Verhaegh G, Jansen CF, Schalken JA, Witjes JA. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: An in vitro study. J Urol 2005;173:1375–80
  • Uchibayashi T, Lee SW, Kunimi K, Ohkawa M, Endo Y, Noguchi M, et al. Studies of effects of anticancer agents in combination with/without hyperthermia on metastasized human bladder cancer cells in chick embryos using the polymerase chain reaction technique. Cancer Chemother Pharmacol 1994;35:S84–7
  • Arends TJ, Falke J, Lammers RJ, Somford DM, Hendriks JC, de Weijert MC, et al. Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World J Urol 2015;33:1411–17
  • Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy vs. chemotherapy alone for superficial bladder cancer. J Urol 1996;155:1227–32
  • Colombo R, Salonia A, Da Pozzo LF, Naspro R, Freschi M, Paroni R, et al. Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: Preliminary clinical experience. Crit Rev Oncol Hematol 2003;47:127–39
  • Farr S, Chess-Williams R, McDermott C. Selective cytotoxicity of gemcitabine on superficial malignant vs normal human urothelial cells and the effects of hyperthermia. Asia Pac J Clin Oncol 2014;10:131
  • Mauroy B, Bonnal JL, Prevost B, Chive M, Lhotellier V, Sozanski JP, et al. Etude de la synergie hyperthermie micro-onde/chimiotherapie intravesicale dans la prevention des recidives des tumeurs superficielles de vessie. [Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumours of the bladder]. Prog Urol 1999;9:69–80
  • Wallner KE, Banda M, Li GC. Hyperthermic enhancement of cell killing by mitomycin C in mitomycin C-resistant Chinese hamster ovary cells. Cancer Res 1987;47:1308–12
  • Moskovitz B, Halachmi S, Moskovitz M, Nativ O, Nativ O. 10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer. Future Oncol 2012;8:1041–9
  • Volpe A, Racioppi M, Bongiovanni L, D’Agostino D, Totaro A, D’Addessi A, et al. Thermochemotherapy for non-muscle-invasive bladder cancer: Is there a chance to avoid early cystectomy? Urol Int 2012;89:311–18
  • Maffezzini M, Campodonico F, Canepa G, Manuputty EE, Tamagno S, Puntoni M. Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression. Cancer Chemother Pharmacol 2014;73:925–30
  • Arends TJ, van der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol 2014;192:708–13
  • Kiss B, Schneider S, Thalmann GN, Roth B. Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer? Int J Urol 2015;22:158–62
  • Sooriakumaran P, Chiocchia V, Dutton S, Pai A, Ayres BE, Le Roux P, et al. Predictive factors for time to progression after hyperthermic mitomycin C treatment for high-risk non-muscle invasive urothelial carcinoma of the bladder: An observational cohort study of 97 patients. Urol Int 2015. doi: 10.1159/000435788. Epub 2015 Aug 6
  • Lüdecke G, Hasner F, Hanitzsch H, Schmidt M. The German study group of intravesical hyperthermia-chemotherapy in non-muscle-invasive bladder cancer presents their long-term results in efficacy and tolerability for optimized adjuvant therapy and bladder preservation. J Clin Oncol 2013;31:S
  • Lüdecke G, Shchafer L, Nativ O, Witzsch U, Hanitzsch H, Hasner F, et al. Radiofrequence induced hyperthermia chemotherapy (RIHTC) in high-risk non-muscle invasive bladder cancer (NMIBC): Multiinstitutional, international outcome analysis of 271 treated patients with a follow-up time of more than 2 years. Eur Urol 2015;14:e949
  • Arends TJH, Nativ O, Maffezzini M, De Cobelli O, Van Der Heijden AG, Witjes JA. Results of the first randomized controlled trial comparing intravesical radiofrequency induced chemohyperthermia with mitomycin-C vs. BCG for adjuvant treatment of patients with intermediate-and high-risk non-muscle invasive bladder cancer. Eur Urol 2015;14:e944
  • Colombo R, Da Pozzo LF, Lev A, Salonia A, Rigatti P, Leib Z, et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol 1998;159:783–7
  • Rigatti P, Lev A, Colombo R. Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study. Eur Urol 1991;20:204–10
  • van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46:65–71; discussion: 72
  • Witjes AJ, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: Experience of the European Synergo working party. World J Urol 2009;27:319–24
  • Halachmi S, Moskovitz B, Maffezzini M, Conti G, Verweij F, Kedar D, et al. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol 2011;29:259–64
  • Ayres BE, Connor A, Corbishley C, Bailey MJ. Radiofrequency hyperthermia and mitomcin C for the management of frail patients with high-risk non-muscle invasive bladder cancer who fail intravesical BCG treatment. BJU Int 2010;106:8
  • Colombo R, Brausi M, Da Pozzo L, Salonia A, Montorsi F, Scattoni V, et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion. Eur Urol 2001;39:95–100
  • Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 2011;107:912–18
  • Kelly JD, Buckley L, Devall AJ, Loubière LS, Barnwell JM, Feneley MR, et al. HYMN: a randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette–Guerin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer (NMIBC) following induction or maintenance therapy. Manchester: BAUS meeting, 2015
  • Ekin RG, Akarken I, Zorlu F, Tarhan H, Kucuk U, Yildirim Z, et al. Intravesical bacillus Calmette–Guerin vs. chemohyperthermia for high-risk non-muscle-invasive bladder cancer. Can Urol Assoc J 2015;9:E278–83
  • Nair R, Pai A, Kaul A, Ayres B, Bailey M, Perry M, et al. Challenging the gold standard: A comparison of long-term disease specific outcomes for high-risk non-muscle invasive bladder cancer treated with mitomycin hyperthermia and radical cystectomy. Eur Urol 2014;13:e1109
  • Rath-Wolfson L, Moskovitz B, Dekel Y, Kugel V, Koren R. Combined intravesical hyperthermia and mitomycin chemotherapy: A preliminary in vivo study. Int J Exp Pathol 2003;84:145–52
  • Hashimoto T, Hisazumi H, Nakajima K, Matsubara F. Studies on endocrine changes induced by 8 MHz local radiofrequency hyperthermia in patients with bladder cancer. Int J Hyperthermia 1991;7:551–7
  • Hasner F, Thueroff S, Chaussy C. Combined thermochemotherapy (Synergo) in non muscle invasive bladder cancer (NMIBC): 8 year follow up of a prospective monocentric cohort study. Urology 2009;74:S145
  • Ekin RG, Akarken I, Cakmak O, Tarhan H, Celik O, Ilbey YO, et al. Results of intravesical chemo-hyperthermia in high-risk non-muscle invasive bladder cancer. Asian Pac J Cancer Prev 2015;16:3241–5
  • Lüdecke GC, Schafer L, Weidner W, Hasner F, Hanitzsch H, Schmidt M. Organ preservation in high- and extreme high risk non-muscle-invasive bladder cancer (NMIBC): Outcome analysis of an interventional cohort study of the German Hyperthermia Chemotherapy Group in efficacy and side effects. Eur Urol 2013;12:e707–8